Pfizer sent its first shipment of Retacrit to wholesalers Nov. 12 at a list price of $11.03 per 1,000 units. This is a 33 percent discount on Epogen and a 57 percent discount on Procrit.
Retracrit was approved by the FDA in May 2018 as a red blood cell-producing stimulant.
With the market launch, Pfizer now has three biosimilars available in the U.S.
More articles on pharmacy:
AstraZeneca sells respiratory drug for $1.5B
Express Scripts to launch formulary for lower list price drugs
Nestle pays $98M for increased stake in food allergy drugmaker Aimmune
